SMN1 and proximal spinal muscular atrophy: Their potential has been demonstrated by the United States Food and Drug Administration’s (FDA) approval of risdiplam for the treatment of spinal muscular atrophy (SMA), where it promotes the inclusion of exon 7 in SMN2, whose product then compensates for SMN1-inactivating mutations.